Taken together, these strategies of using 177Lu-labeled chemotherapeutic drug-loaded nanosystems with BBN peptides for combined targeted therapy have shown promise in their application to GRPR-positive breast cancers. This evidence concerns the gene GRPR and breast carcinoma.